← Back to Search

Behavioural Intervention

Digital Guided Meditation and Relaxation for Delirium (DREAMS Trial)

N/A
Waitlist Available
Led By Azra Bihorac, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients ≥ 18 years admitted to University of Florida (UF) Health Shands Hospital who do not have a positive Confusion Assessment Method (CAM) score, including ICU patients.
Be older than 18 years old
Must not have
Age: < 18 years
Patient is intubated and cannot communicate.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up daily up to 14 days
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a digital system called D.R.E.A.M.S. that creates a calming environment for ICU patients. It aims to reduce stress by managing noise and light. The goal is to prevent delirium, a common issue in critically ill patients.

Who is the study for?
This trial is for adults over 18 years old at UF Health Shands Hospital who are not currently experiencing delirium. It's open to ICU patients unless they expect to stay less than a day, can't communicate due to intubation, have trouble using the tech equipment, severe cognitive issues like advanced dementia, or recent major brain events/surgery.
What is being tested?
The D.R.E.A.M.S. study tests if a high-tech guided meditation and relaxation system can help prevent mental and emotional problems that often happen after critical illness or being in intense medical environments which could lead to delirium.
What are the potential side effects?
Since this intervention involves technology-based meditation, side effects might be minimal but could include discomfort with wearing the equipment or possible stress from engaging with digital reality tools.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older, admitted to UF Health Shands Hospital, and not confused.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
I am currently intubated and unable to speak.
Select...
I cannot use or wear the DREAMS equipment.
Select...
I was admitted to the ICU recently for a brain-related issue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~daily up to 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and daily up to 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessment of anxiety measured by Hospital Anxiety and Depression Scale (HADS) questionnaire
Blood Pressure -Systolic
Heart Rate
Secondary study objectives
Amount of sedatives requested by subjects
Amount of sedatives subjects receive
DREAMS usability and acceptability questionnaire
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mediation and Relaxation InterventionExperimental Treatment1 Intervention
Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for delirium include pharmacological interventions like antipsychotics, which work by modulating neurotransmitter activity to reduce symptoms such as agitation and hallucinations. Non-pharmacological approaches, such as environmental modifications and cognitive therapies, aim to reduce stressors and improve orientation and cognitive function. The Immersive Digital Reality-Augmenting System (D.R.E.A.M.S.) aligns with these non-pharmacological strategies by providing a controlled, engaging environment that can mitigate stressors and enhance cognitive and emotional outcomes. This is crucial for delirium patients as it helps stabilize their mental state, reduces confusion, and promotes recovery without the side effects associated with medications.

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,394 Previous Clinical Trials
767,034 Total Patients Enrolled
5 Trials studying Delirium
693 Patients Enrolled for Delirium
Azra Bihorac, MDPrincipal InvestigatorUniversity of Florida
5 Previous Clinical Trials
699 Total Patients Enrolled
2 Trials studying Delirium
201 Patients Enrolled for Delirium

Media Library

Technology based guided meditation and relaxation (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT03385993 — N/A
Delirium Clinical Trial 2023: Technology based guided meditation and relaxation Highlights & Side Effects. Trial Name: NCT03385993 — N/A
Technology based guided meditation and relaxation (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03385993 — N/A
Delirium Research Study Groups: Mediation and Relaxation Intervention
~0 spots leftby Dec 2024